middle.news
How Patrys’ New Injectable Antipsychotic Could Transform $2B Delirium Market
9:22am on Wednesday 26th of November, 2025 AEDT
•
Healthcare
Read Story
How Patrys’ New Injectable Antipsychotic Could Transform $2B Delirium Market
9:22am on Wednesday 26th of November, 2025 AEDT
Key Points
Acquisition of Reliis adds injectable Quetiapine (RLS-2201) targeting delirium
Addresses a US$2 billion+ global market with no approved acute delirium treatments
Near-term clinical milestones include Phase 0 and Phase I trials planned
Deal includes issuing 110 million shares and 70 million performance rights
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PATRYS (ASX:PAB)
OPEN ARTICLE